Phaseline

Targets › GASTRIN

GASTRIN: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Aug 2027.

Open in Phaseline: the race on GASTRIN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City of Hope Medical CenterGastrin 17 (GAST-17)
Gastrin-17 receptor agonist
GASTRINPhase 2Type 1 Diabetes MellitusAug 2027

Conditions

Type 1 Diabetes Mellitus (1)

Modalities

mixed (1)

Companies

City of Hope Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.